NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McDonagh MS, Selover D, Santa J, et al. Drug Class Review: Agents for Overactive Bladder: Final Report Update 4 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Mar.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Agents for Overactive Bladder

Drug Class Review: Agents for Overactive Bladder: Final Report Update 4 [Internet].

Show details

References

1.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. [PubMed: 12559262]
2.
Koda-Kimble, et al., editors. Applied therapeutics: the clinical use of drugs. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2001.
3.
Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chronic management. Clinical Practice Guideline #2 AHCPR Publication No. 96-0682. Rockville, MD: Agency for Healthcare Policy and Research; 1996.
4.
Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. Journal of Urology. 2003;169(3):843–848. [PubMed: 12576796]
5.
Couture JA, Valiquette L. Urinary incontinence. Annals of Pharmacotherapy. 2000;34(5):646–655. [PubMed: 10852094]
6.
Schmidt RA, Zermann DH, Doggweiler R. Urinary incontinence update: old traditions and new concepts. Advances in Internal Medicine. 1999;44:19–57. [PubMed: 9929704]
7.
McEvoy, et al., editors. AHFS Drug Information 2002. Bethesda, MD: Society of Health System Pharmacists, Inc.; 2002.
8.
Ortho McNeil Janssen. Ditropan XL package insert. 2008
9.
Pharmacia and Upjohn. Detrol LA package insert. 2008
10.
Trospium chloride (Sanctura): another anticholinergic for overactive bladder. Medical Letter on Drugs & Therapeutics. 2004;46(1188):63–64. [PubMed: 15289745]
11.
Novartis. Enablex (darifenacin) package insert; 2008
12.
Astellas. VESIcare (solifenacin) package insert; 2008
13.
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Archives of Internal Medicine. 1997;157(4):1531–1537. [PubMed: 9236554]
14.
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Archives of Internal Medicine. 1991;151(9):1825–1832. [PubMed: 1888249]
15.
Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews. 2005;3 [PubMed: 16034974]
16.
Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. European Urology. 2005;48(1):5–26. [PubMed: 15885877]
17.
Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews. 2002;3 [PubMed: 12137711]
18.
Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Annals of Internal Medicine. 2008 Mar 18;148(6):459–473. [PubMed: 18268288]
19.
Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. British Medical Journal. 2003;326(7394):841–844. [PMC free article: PMC153465] [PubMed: 12702614]
20.
Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. European Urology. 2006 Oct;50(4):675–683. [PubMed: 16930813]
21.
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology. 1998;81(6):801–810. [PubMed: 9666761]
22.
Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. Journal of Urology. 1999;161(6):1809–1812. [PubMed: 10332441]
23.
Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clinic Proceedings. 2001;76(4):358–363. [PubMed: 11322350]
24.
Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clinical Therapeutics. 2004 Jul;26(7):1026–1036. [PubMed: 15336467]
25.
Birns J, Lukkari E, Malone-Lee JG, et al. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU International. 2000;85(7):793–798. [PubMed: 10792154]
26.
Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. European Urology. 2005;48(1):102–109. [PubMed: 15936869]
27.
Chapple CR, Arano P, Bosch JHR, De Ridder D, Kramer A, Ridder A. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.[erratum appears in BJU Int. 2004 May;93(7):1135] BJU International. 2004;93(1):71–77. [PubMed: 14678372]
28.
Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. European Urology. 2005;48(3):464–470. [PubMed: 15990220]
29.
Chu FM, Dmochowski RR, Lama DJ, Anderson RU, Sand PK. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. American Journal of Obstetrics & Gynecology. 2005;192(6):1849–1854. [PubMed: 15970828]
30.
Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Journal of Urology. 2001;166(1):140–145. [PubMed: 11435842]
31.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clinic Proceedings. 2003;78(6):687–695. [PubMed: 12934777]
32.
Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–242. [PubMed: 12893326]
33.
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal. 1999;10(5):283–289. [PubMed: 10543335]
34.
Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World Journal of Urology. 2003;20(6):392–399. [PubMed: 12811500]
35.
Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology. 2004 Aug;22(4):251–256. [PubMed: 15455256]
36.
Homma Y, Paick JS, Lee JG, Kawabe K. Japanese Korean Tolterodine Study G. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International. 2003;92(7):741–747. [PubMed: 14616458]
37.
Lee JG, Hong JY, Choo M-S, et al. Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. International Journal of Urology. 2002;9(5):247–252. [PubMed: 12060436]
38.
Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU International. 2002;90:375–380. [PubMed: 12175392]
39.
Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. British Journal of Urology. 1995;75(4):452–456. [PubMed: 7788255]
40.
Milani R, Scalambrino S, Milia R, et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int Urogynecol J. 1993;4(1):3–8.
41.
Nilsson CG, Lukkari E, Haarala M, Kivela A, Hakonen T, Kiilholma P. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourology & Urodynamics. 1997;16(6):533–542. [PubMed: 9353802]
42.
Radomski S, Caley B, Reiz JL, Miceli PC, Harsanyi Z, Darke AC. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. Current Medical Research and Opinion. 2004;20(2):249–253. [PubMed: 15006020]
43.
Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. International Urogynecology Journal. 2004 Jul-Aug;15(4):243–248. [PubMed: 15517668]
44.
Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET) Current Medical Research & Opinion. 2002;18(4):177–184. [PubMed: 12201616]
45.
Swift S, Garely A, Dimpfl T, Payne C. Tolterodine Study G. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. International Urogynecology Journal. 2003;14(1):50–54. discussion 54–55. [PubMed: 12601517]
46.
Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine Study G. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–421. [PubMed: 11248608]
47.
Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstetrics & Gynecology. 2000;95(5):718–721. [PubMed: 10775736]
48.
Zeegers AGM, Kiesswetter H, Kramer A, Jonas U. Conservative therapy of frequency, urgency and urge incontinence: A double-blind clinical trial of flavoxate hydrochloride, oxybutinin chloride, emepronium bromide and placebo. World Journal of Urology. 1987;5(1):57–61.
49.
Malone-Lee JG. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder. Reviews in Contemporary Pharmacotherapy. 2000;11(1):29–42.
50.
Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International. 2004;93(3):303–310. [PubMed: 14764127]
51.
Badia X, Ibarz R. Health-related quality of life issues in urinary urge incontinence. Expert Review of Pharmacoeconomics & Outcomes Research. 2002;2(4):357–365. [PubMed: 19807442]
52.
Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU International. 1999;83(6):583–590. [PubMed: 10233562]
53.
O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics. 1998;14(5):531–539. [PubMed: 10344916]
54.
Malone-Lee J, Eriksson M, Olofsson S, Lidberg The comparative tolerability and efficacy of tolterodine 2 mg bid versus oxybutynin 2.5/5 mg bid in the treatment of the overactive bladder. Neurourology & Urodynamics. 1998;17(4):163–164.
55.
Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World Journal of Urology. 2001;19(2):141–147. [PubMed: 11374317]
56.
Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care. 2002;8(19 Suppl):S616–630. [PubMed: 12516956]
57.
Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care. 2002;8(19 Suppl):S608–615. [PubMed: 12516955]
58.
Okano GJ, Pleil AM, Reese PR, et al. Effects of long-term tolterodine treatment on physical and symptom aspects of health-related quality of life in overactive bladder patients. Value in Health. 2002;5(3):278.
59.
Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Hepac Health Economics in Prevention & Care. 2001;2(2):69–75.
60.
Rogers R, Bachmann G, Jumadilova Z, Sun F, Morro JD, Guan Z, Bavendam T. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(11):1551–1557. [PubMed: 18685795]
61.
Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU International. 2008 Jul;102(2):208–213. [PubMed: 18325056]
62.
Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50(6A Suppl):90–96. [PubMed: 9426760]
63.
Alloussi S, Laval KU, Eckert R, et al. Trospium chloride (Spasmo-lyt(R)) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Drug Assessment. 1999;2(Part 1):27–40.
64.
Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU International. 2000;85(6):659–664. [PubMed: 10759661]
65.
Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. Journal of Urology. 2005 Apr;173(4):1214–1218. [PubMed: 15758755]
66.
Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology. 2004 Nov;172(5 Pt 1):1919–1924. [PubMed: 15540755]
67.
Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation. 2000;19(2):83–91.
68.
Chapple CR, Parkhouse H, Gardener C, Milroy EJ. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. British Journal of Urology. 1990;66(5):491–494. [PubMed: 2249117]
69.
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Journal of Urology. 2002;168(2):580–586. [PubMed: 12131314]
70.
Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology. 2004 Apr;45(4):420–429. discussion 429. [PubMed: 15041104]
71.
Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 2001;98(1):97–102. [PubMed: 11516807]
72.
Khullar V, Hill S, Laval K-U, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. Urology. 2004;64:269–274. [PubMed: 15302476]
73.
Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology. 2004;171(2 Pt 1):752–756. [PubMed: 14713803]
74.
Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatrics Society. 2001;49(6):700–705. [PubMed: 11454106]
75.
Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology. 1999;161(5):1551–1555. [PubMed: 10210394]
76.
Muskat Y, Bukovsky I, Schneider D, Langer R. The use of scopolamine in the treatment of detrusor instability. Journal of Urology. 1996 Dec;156(6):1989–1990. [PubMed: 8911372]
77.
Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology. 1998;81(1):42–48. [PubMed: 9467475]
78.
Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU International. 2005 Mar;95(4):580–586. [PubMed: 15705084]
79.
Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: A randomized controlled trial. Age & Ageing. 1995;24(4):287–291. [PubMed: 7484484]
80.
Van Kerrebroeck PE, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourology & Urodynamics. 1998;17(5):499–512. [PubMed: 9776013]
81.
Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. Journal of Urology. 2004;171(6 I):2311–2315. [PubMed: 15126811]
82.
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society. 2002;50(5):799–807. [PubMed: 12028164]
83.
Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research & Opinion. 2007 Oct;23(10):2347–2358. [PubMed: 17706004]
84.
Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU International. 2007 Jul;100(1):107–110. [PubMed: 17552957]
85.
Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar;71(3):449–454. [PubMed: 18342185]
86.
Hill S, Khullar V, Wyndaele J-J, Lheritier K. Darifenacin Study G. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal. 2006 May;17(3):239–247. [PubMed: 15999217]
87.
Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006 Aug;68(2):328–332. [PubMed: 16904446]
88.
Kelleher C, Cardozo L, Kobashi K, Lucente V. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. International Urogynecology Journal. 2006 Jun;17(4):382–388. [PubMed: 16283422]
89.
Nitti VW, Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU International. 2006 Jun;97(6):1262–1266. [PubMed: 16686723]
90.
Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, Study G. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006 Apr;67(4):731–736. discussion 736. [PubMed: 16618562]
91.
Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU International. 2006 May;97(5):1003–1006. [PubMed: 16643482]
92.
Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006 Feb;67(2):275–280. [PubMed: 16461077]
93.
Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International. 2006 Mar;97(3):540–546. [PubMed: 16469022]
94.
Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. Journal of Urology. 2007 Sep;178(3 Pt 1):978–983. discussion 983–974. [PubMed: 17632131]
95.
Wein AJ, Khullar V, Wang JT, et al. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU International. 2007 Feb;99(2):360–363. [PubMed: 17155987]
96.
Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.[erratum appears in Int J Clin Pract. 2006 Jul;60(7):890] International Journal of Clinical Practice. 2006 Jan;60(1):119–126. [PubMed: 16409440]
97.
Brubaker L, FitzGerald MP, Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. International Urogynecology Journal. 2007 Jul;18(7):737–741. [PubMed: 17131169]
98.
Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU International. 2006 Jun;97(6):1256–1261. [PubMed: 16686722]
99.
Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Current Medical Research & Opinion. 2006 Jan;22(1):41–48. [PubMed: 16393429]
100.
Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. International Urogynecology Journal. 2006 Sep;17(5):512–519. [PubMed: 16625311]
101.
Abrams P, Swift S, Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. European Urology. 2005 Sep;48(3):483–487. [PubMed: 16005564]
102.
Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World Journal of Urology. 2005 Sep;23(4):263–270. [PubMed: 16151816]
103.
Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, Study G. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008 Sep;72(3):488–493. [PubMed: 18639327]
104.
Appell RA. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. Current Urology Reports. 2002;3(5):343–344. [PubMed: 12354340]
105.
Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World Journal of Urology. 2005 Sep;23(4):248–252. [PubMed: 16096831]
106.
Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. European Urology. 2007 Oct;52(4):1195–1203. [PubMed: 17574730]
107.
Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. International Urogynecology Journal. 2006 Sep;17(5):502–511. [PubMed: 16724169]
108.
Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20(4):470–475. [PubMed: 10772377]
109.
Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. American Journal of Managed Care. 2005;11(4 Suppl):S121–129. [PubMed: 16161385]
110.
Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. American Journal of Managed Care. 2005;11(4 Suppl):S140–149. [PubMed: 16161387]
111.
Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The Speed of Onset of Therapeutic Assessment Trial (STAT) Clinical Therapeutics. 2002;24(4):616–628. [PubMed: 12017406]
112.
Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opinion on Pharmacotherapy. 2001;2(10):1685–1701. [PubMed: 11825311]
113.
Abrams P, Malone-Lee J, Jacquetin B, Wyndaele JJ, Wein A, et al. Twelve month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs & Aging. 2001;18(7):551–560. [PubMed: 11482747]
114.
Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. European Urology. 2002;41(6):588–595. [PubMed: 12074774]
115.
Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Safety. 2001;24(9):703–713. [PubMed: 11522122]
116.
Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? Journal of Urology. 2002;168(3):1027–1031. [PubMed: 12187215]
117.
Ouslander JG, Maloney C, Grasela TH, Rogers L, Walawander CA. Implementation of a nursing home urinary incontinence management program with and without tolterodine. Journal of the American Medical Directors Association. 2001;2(5):207–214. [PubMed: 12812542]
118.
Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology. 1999;54(3):420–423. [PubMed: 10475346]
119.
Haab F, Cardozo L, Chapple C, Ridder AM. Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. European Urology. 2005 Mar;47(3):376–384. [PubMed: 15716204]
120.
Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU International. 2006 Nov;98(5):1025–1032. [PubMed: 16879437]
121.
Michel MC, de la Rosette JJ, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. European Urology. 2005;48(1):110–115. [PubMed: 15967259]
122.
Salvatore S, Khullar V, Cardozo L, Milani R, Athanasiou S, Kelleher C. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 2005;119(2):237–241. [PubMed: 15808387]
123.
Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. Journal of Urology. 2001;165(5):1452–1456. [PubMed: 11342895]
124.
Lee JG, Hong JY, Choo MS, Kwon HY, Chung DYK. S T. Tolterodine: as effective but better tolerated than Oxybutinin in Asian patients with symptoms of overactive bladder (Abstract) Proceedings of the International Continence Society. 2001
125.
Armstrong RB, Luber KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. International Urology & Nephrology. 2005;37(2):247–252. [PubMed: 16142551]
126.
Takei M, Homma Y. The Japanese Tolterodine Study G. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. International Journal of Urology. 2005;12(5):456–464. [PubMed: 15948744]
127.
Madersbacher H, Knoll M. Lntravesical application of oxybutynine: Mode of action in controlling detrusor hyperreflexia. Preliminary results. European Urology. 1995;28(4):340–344. [PubMed: 8575504]
128.
Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. Journal of the American Geriatrics Society. 1995;43(6):610–617. [PubMed: 7775717]
129.
Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Current Medical Research & Opinion. 2007 Nov;23(11):2697–2704. [PubMed: 17892634]
130.
Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. European Urology. 2005 Sep;48(3):471–477. [PubMed: 15990219]
131.
Wagg A, Wyndaele JJ, Sieber P, Wagg A, Wyndaele J-J, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. American Journal Geriatric Pharmacotherapy. 2006 Mar;4(1):14–24. [PubMed: 16730617]
132.
Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. European Urology. 2007 Apr;51(4):1054–1064. discussion 1064. [PubMed: 17097217]
133.
Capo JP Jr, Laramee C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. International Journal of Clinical Practice. 2008 Jan;62(1):39–46. [PubMed: 18036164]
134.
Brynne N, Bottiger Y, Hallen B, Bertilsson L. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. British Journal of Clinical Pharmacology. 1999;47(2):145–150. [PMC free article: PMC2014166] [PubMed: 10190648]
135.
Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clinical Pharmacology & Therapeutics. 1998;63(5):529–539. [PubMed: 9630826]
136.
Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. British Journal of Clinical Pharmacology. 1999;48(4):564–572. [PMC free article: PMC2014365] [PubMed: 10583027]
137.
Brynne N, Stahl MM, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. International Journal of Clinical Pharmacology & Therapeutics. 1997;35(7):287–295. [PubMed: 9247842]
138.
Brynne N, Svanstrom C, Aberg-Wistedt A, Hallen B, Bertilsson L. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. British Journal of Clinical Pharmacology. 1999;48(4):553–563. [PMC free article: PMC2014382] [PubMed: 10583026]
139.
Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. [erratum appears in JAMA. 2007 Mar 21:297(11):1195] JAMA. 2006 Nov 15;296(19):2319–2328. [PubMed: 17105794]
140.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2008 [PubMed: 19070418]
141.
Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Journal of Urology. 2006 Mar;175(3 Pt 1):999–1004. discussion 1004. [PubMed: 16469601]
142.
Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol. 2009;55:472–481. [PubMed: 18583022]
143.
Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. Journal of Urology. 2008 Sep;180(3):1034–1041. [PubMed: 18639297]
144.
Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU International. 2008 Nov;102(9):1133–1139. [PubMed: 18510659]
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK47186

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...